Farletuzumab Ecteribulin Shows Early Activity in Platinum-Resistant Ovarian Cancer
June 21, 2022 11:03 amby Chris Ryan
The antibody-drug conjugate farletuzumab ecteribulin demonstrated notable antitumor activity with a manageable safety profile in patients with platinum-resistant ovarian cancer.
The antibody-drug conjugate (ADC) farletuzumab ecteribulin (MORab-202) demonstrated notable antitumor activity with a manageable safety profile in